Pfizer Fails To Delay Chantix Trial Despite New Study

Law360, New York (October 16, 2012, 11:22 PM EDT) -- An Alabama federal judge on Tuesday refused to grant Pfizer Inc. a stay in the upcoming trial over allegations that its smoking cessation drug Chantix was linked to depression and suicidal behavior despite the pharmaceutical giant’s new study that it said needed months for consideration.

U.S. District Judge Inge Prytz Johnson shot down Pfizer's arguments that its study, which it says "go[es] directly to the heart of plaintiff's medical causation and punitive damages claims,” was cause to delay the bellwether trial for three months.

The proceedings...
To view the full article, register now.